The Mellanby Centre for Bone Research, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA), University of Liverpool, Liverpool, UK.
Osteoporos Int. 2018 Jun;29(6):1367-1378. doi: 10.1007/s00198-018-4445-5. Epub 2018 Mar 8.
The central and peripheral skeleton was characterised using imaging techniques during 104 weeks of teriparatide treatment. Teriparatide exerts differential effects on the central and the peripheral skeleton. Overall, we did not observe a change in total body bone mineral. Our conclusions are constrained by the study limitations.
Teriparatide stimulates bone formation and resorption and therefore can cause bone gain and loss. We simultaneously characterised the central and peripheral skeleton using imaging techniques to better understand the mechanism of action of teriparatide.
Postmenopausal, osteoporotic women (n = 20, 65.4 ± 5.5 years) were recruited into a 104-week study of teriparatide. Imaging techniques included DXA, quantitative computed tomography (QCT), and high-resolution peripheral quantitative computed tomography (HR-pQCT).
Total lumbar spine areal bone mineral content (aBMC) (+ 11.2%), total lumbar spine areal bone mineral density (aBMD) (+ 8.1%), subregional thoracic spine aBMD (+ 7.5%), lumbar spine aBMC (+ 23.5%), lumbar spine aBMD (+ 11.9%), pelvis aBMC (+ 9.3%), and pelvis aBMD (+ 4.3%) increased. However, skull aBMC (- 5.0%), arms aBMC (- 5.1%), legs aBMC (- 2.9%), and legs aBMD (- 2.5%) decreased. Overall, we did not observe a change in total body bone mineral. Increases in L1-L3 volumetric BMD (vBMD) (+ 28.5%) occurred but there was no change in total proximal femur vBMD. Radius and tibia cortical vBMD (- 3.3 and - 3.4%) and tissue mineral density (- 3.2 and - 3.8%) decreased and there was an increase in porosity (+ 21.2 and + 10.3%). Tibia, but not radius, trabecular inhomogeneity (+ 3.2%), and failure load (+ 0.2%) increased, but cortical thickness (- 3.1%), area (- 2.9%), and pore volume (- 1.6%) decreased.
Teriparatide exerts differential effects on the central and the peripheral skeleton. Central trabecular vBMD (L1-L3) is improved, but there is a concomitant decrease in peripheral cortical vBMD and an increase in porosity. Overall, we did not observe a change in total body bone mineral. We acknowledge that our conclusions may be speculative and are constrained by the technical limitations of the imaging techniques used, the lack of a control group, and the small sample size studied.
在为期 104 周的特立帕肽治疗期间,使用成像技术对中央和外周骨骼进行了特征描述。特立帕肽对中央和外周骨骼有不同的影响。总的来说,我们没有观察到全身骨矿物质的变化。我们的结论受到研究限制的约束。
特立帕肽刺激骨形成和吸收,因此会导致骨丢失和获得。我们同时使用成像技术对中央和外周骨骼进行了特征描述,以更好地了解特立帕肽的作用机制。
招募了 20 名绝经后骨质疏松女性(65.4±5.5 岁)参加特立帕肽为期 104 周的研究。成像技术包括 DXA、定量计算机断层扫描(QCT)和高分辨率外周定量计算机断层扫描(HR-pQCT)。
腰椎全长骨面积骨矿物质含量(aBMC)增加(+11.2%)、腰椎全长骨密度(aBMD)增加(+8.1%)、胸段脊柱亚区骨密度增加(+7.5%)、腰椎全长骨 BMC 增加(+23.5%)、腰椎全长骨 BMD 增加(+11.9%)、骨盆 BMC 增加(+9.3%)、骨盆 BMD 增加(+4.3%)。然而,颅骨 BMC 减少(-5.0%)、手臂 BMC 减少(-5.1%)、腿部 BMC 减少(-2.9%)和腿部 BMD 减少(-2.5%)。总的来说,我们没有观察到全身骨矿物质的变化。L1-L3 容积骨密度(vBMD)增加(+28.5%),但总股骨近端 vBMD 没有变化。桡骨和胫骨皮质 vBMD 减少(-3.3%和-3.4%)和组织矿物质密度减少(-3.2%和-3.8%),孔隙率增加(+21.2%和+10.3%)。胫骨而不是桡骨的小梁不均匀性增加(+3.2%)和失效负荷增加(+0.2%),但皮质厚度减少(-3.1%)、面积减少(-2.9%)和孔体积减少(-1.6%)。
特立帕肽对中央和外周骨骼有不同的影响。中央小梁 vBMD(L1-L3)得到改善,但外周皮质 vBMD 同时下降,孔隙率增加。总的来说,我们没有观察到全身骨矿物质的变化。我们承认,我们的结论可能是推测性的,并受到所使用成像技术的技术限制、缺乏对照组和研究样本量小的限制。